WO2025094054 - METHOD FOR PURIFYING SMALL MULTI-DOMAIN PROTEINS
National phase entry:
Publication Number
WO/2025/094054
Publication Date
08.05.2025
International Application No.
PCT/IB2024/060657
International Filing Date
29.10.2024
Title **
[English]
METHOD FOR PURIFYING SMALL MULTI-DOMAIN PROTEINS
[French]
PROCÉDÉ DE PURIFICATION DE PETITES PROTÉINES À DOMAINES MULTIPLES
Applicants **
IMMUNOCORE LIMITED
Inventors
PATEL, Viren
JOSEPH, Erin
Priority Data
63/594,987
01.11.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4297 | |
| EPO | Filing, Examination, Granting | 65179 | |
| Japan | Filing, Examination, Granting | 4212 | |
| South Korea | Filing, Examination, Granting | 6604 | |
| USA | Filing, Examination, Granting | 18740 |
Total:
99,032
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides a method for purifying a T cell engaging peptide-major histocompatibility complex binding domain (TCE-pMHC) molecule produced by a host cell, the method comprising: isolating a supernatant of a host cell culture comprising the TCE-pMHC molecule to form Product (a), subjecting Product (a) to affinity chromatography wherein the TCE-pMHC molecule is eluted from the affinity chromatography at a pH of about 3.0 to about 4.0 to form Product (b); neutralizing Product (b) by adding MES buffer with a pH of less than 7.0 to form Product (c), wherein Product (c) has a pH of about 5.0 to about 7.0; and subjecting Product (c) to anion exchange chromatography to form Product (d), wherein the pMHC binding domain and the T cell engaging immune effector domain are capable of binding to a pMHC complex and a T cell respectively.[French]
La présente divulgation concerne un procédé de purification d'une molécule à domaine de liaison de complexe majeur d'histocompatibilité (TCE-pMHC) de peptide d'activation des lymphocytes T produite par une cellule hôte, le procédé comprenant les étapes consistant à : isoler un surnageant d'une culture de cellules hôtes comprenant la molécule TCE-pMHC pour former un produit (a), soumettre le produit (a) à une chromatographie d'affinité, la molécule TCE-pMHC étant éluée à partir de la chromatographie d'affinité à un pH d'environ 3,0 à environ 4,0 pour former un produit (b) ; un produit neutralisant (b) par ajout d'un tampon MES ayant un pH inférieur à 7,0 pour former un produit (c), le produit (c) ayant un pH d'environ 5,0 à environ 7,0 ; et soumettre le produit (c) à une chromatographie par échange d'anions pour former un produit (d), le domaine de liaison pMHC et le domaine effecteur immunitaire d'activation des lymphocytes T étant capables de se lier à un complexe pMHC et à un lymphocyte T respectivement.